Last reviewed · How we verify
NCT06633588: SPADE
Decolonization Efficacy of Polyhexanide vs. Mupirocin
Phase 4 trial testing Polyhexanide in Staphylococcus Aureus in 24 participants. Currently enrolling.
30 March 2027
Quick facts
| Lead sponsor | Swiss Paraplegic Research, Nottwil |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 24 |
| Start date | 1 May 2025 |
| Primary completion | 30 March 2027 |
| Estimated completion | 30 April 2027 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- Polyhexanide — full drug profile →
- Mupirocin and Chlorhexidine — full drug profile →
Conditions studied
- Staphylococcus Aureus — all drugs for Staphylococcus Aureus →
- Colonization, Asymptomatic — all drugs for Colonization, Asymptomatic →
Sponsor
Swiss Paraplegic Research, Nottwil — full company profile →
Who can join
18 and older, any sex, with Staphylococcus Aureus or Colonization, Asymptomatic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This pilot randomized controlled trial evaluates the feasibility, tolerability, and preliminary efficacy of a decolonization regimen using polyhexanide in reducing Staphylococcus aureus colonization in the preoperative phase of elective spine surgery, compared to the standard mupirocin and chlorhexidine regimen. The trial involves 24 participants randomized into two groups: one receiving polyhexanide and the other receiving mupirocin and chlorhexidine. The primary outcome is the randomization rate, with secondary outcomes including other feasibility outcomes, tolerability, and efficacy measures such as the reduction in S. aureus colony-forming units (CFUs) and changes in the nasal and skin microbiome composition.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06633588
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Staphylococcus Aureus
Currently open trials in the same condition.
- NCT06749457 — A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Dis · Phase 1, PHASE2 · recruiting
- NCT06283355 — Comparing Single Versus Repeat NMT on the Diversity of the Neonatal Nasal Microbiome · Phase 1 · recruiting
- NCT06290557 — First-in-man Single-dose and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy ofHY-133 · Phase 1 · recruiting
- NCT05695196 — Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant · Phase 1 · active not recruiting
- NCT05094570 — Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP · Phase 4 · recruiting
Other Swiss Paraplegic Research, Nottwil trials
Trials by the same sponsor.
- NCT07456722 — Cardiac Morphology and Function in Individuals With Autonomic Dysreflexia · not yet recruiting
- NCT06905470 — The Effects of Eccentric Compared to Standard Strength Training in Primary Spinal Cord Injury Rehabilitation · NA · not yet recruiting
- NCT07165353 — Virtual Walking to Reduce Chronic Neuropathic Pain in Subjects With SCI · NA · recruiting
- NCT06892080 — Urine Incontinence Occurrence and Sexual Hormones in Women With Chronic Spinal Cord Injury/Disease - a Pilot Study · recruiting
- NCT06710808 — VIRTUAL WALKING AND TRANSCRANIAL DIRECT CURRENT STIMULATION FOR CHRONIC NEUROPATHIC PAIN DUE TO SPINAL CORD INJURY · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06633588 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Swiss Paraplegic Research, Nottwil
- Last refreshed: 28 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06633588.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing